Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group Has $1.27 Million Position in Kenvue Inc. (NYSE:KVUE)

Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group grew its holdings in Kenvue Inc. (NYSE:KVUE) by 2.1% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 53,003 shares of the company’s stock after purchasing an additional 1,075 shares during the quarter. Kenvue comprises 0.7% of Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group’s portfolio, making the stock its 29th biggest holding. Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group’s holdings in Kenvue were worth $1,271,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in KVUE. Pittenger & Anderson Inc. bought a new stake in shares of Kenvue in the first quarter valued at about $30,000. TruNorth Capital Management LLC acquired a new stake in Kenvue during the first quarter valued at approximately $36,000. Clarity Asset Management Inc. acquired a new stake in Kenvue during the fourth quarter valued at approximately $45,000. Continuum Advisory LLC boosted its holdings in Kenvue by 2,071.1% during the first quarter. Continuum Advisory LLC now owns 1,954 shares of the company’s stock valued at $47,000 after purchasing an additional 1,864 shares in the last quarter. Finally, Rossby Financial LCC acquired a new stake in Kenvue during the first quarter valued at approximately $52,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on KVUE shares. Evercore ISI initiated coverage on shares of Kenvue in a research note on Monday, March 24th. They issued an “in-line” rating and a $25.00 target price for the company. Barclays dropped their price objective on shares of Kenvue from $23.00 to $22.00 and set an “equal weight” rating for the company in a research report on Tuesday. UBS Group dropped their price objective on shares of Kenvue from $25.00 to $23.00 and set a “neutral” rating for the company in a research report on Thursday. Redburn Atlantic started coverage on shares of Kenvue in a research report on Thursday, April 10th. They set a “neutral” rating and a $23.50 target price for the company. Finally, Citigroup dropped their target price on shares of Kenvue from $24.50 to $22.00 and set a “neutral” rating for the company in a research report on Tuesday. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $24.71.

Kenvue Stock Up 1.4%

Shares of Kenvue stock traded up $0.31 during trading hours on Friday, reaching $22.16. 713,479 shares of the company’s stock were exchanged, compared to its average volume of 16,254,618. The company has a 50 day moving average of $22.24 and a two-hundred day moving average of $22.29. Kenvue Inc. has a fifty-two week low of $17.85 and a fifty-two week high of $25.17. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.63. The stock has a market cap of $42.53 billion, a P/E ratio of 40.30, a P/E/G ratio of 3.40 and a beta of 0.83.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.01. Kenvue had a net margin of 6.90% and a return on equity of 20.87%. The business had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.69 billion. During the same period last year, the business posted $0.28 EPS. Kenvue’s revenue was down 3.9% on a year-over-year basis. On average, sell-side analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.